BACKGROUND: Factors that are predictive of carrying BRCA1 and BRCA2 germline mutations in patients with breast carcinoma are awaited widely. The genetically homogeneous Sardinian population may be useful for defining the role of such genetic alterations further through a clinical evaluation program. METHODS: One hundred two of 659 patients with breast carcinoma (15.5%) who were collected consecutively had a family history of breast carcinoma and were screened for BRCA1/2 mutations by denaturing high-performance liquid chromatography and DNA sequencing. RESULTS: Three deleterious germline BRCA1/2 mutations were detected in 15 of 102 families (14.7%), including 13 families (86.7%) with BRCA2 mutations and 2 families (13.3%) with BRCA1 mutations. A single variant, BRCA2-8765delAG, was the most recurrent mutation in the series and was found in 12 of 102 families (11.8%) and in 18 of 657 patients (2.7%). The average age at diagnosis was significantly younger in families with BRCA1/2 mutations (48.6 yrs) compared with the age of patients who had no detectable mutation (52.9 yrs; P = 0.039). Moreover, BRCA1/2 mutations were found at a significantly higher rate in families who had at least 1 member with ovarian carcinoma or male breast carcinoma (5 of 12 families; 41.7%) than in families without such an association (10 of 90 families; 11.1%; P = 0.003). CONCLUSIONS: BRCA2 mutations were approximately 6 times more prevalent than BRCA1 mutations. A diagnosis of breast carcinoma before age 50 years, ovarian carcinoma, male breast carcinoma, and 3 affected generations all were associated significantly with BRCA1/2 mutations. Although the current findings provided further support for the hypothesis that additional breast carcinoma susceptibility genes remain to be identified, such indicators of the presence of BRCA1/2 mutations may be useful in counseling patients about undergoing genetic testing. Copyright 2005 American Cancer Society.
BACKGROUND: Factors that are predictive of carrying BRCA1 and BRCA2 germline mutations in patients with breast carcinoma are awaited widely. The genetically homogeneous Sardinian population may be useful for defining the role of such genetic alterations further through a clinical evaluation program. METHODS: One hundred two of 659 patients with breast carcinoma (15.5%) who were collected consecutively had a family history of breast carcinoma and were screened for BRCA1/2 mutations by denaturing high-performance liquid chromatography and DNA sequencing. RESULTS: Three deleterious germline BRCA1/2 mutations were detected in 15 of 102 families (14.7%), including 13 families (86.7%) with BRCA2 mutations and 2 families (13.3%) with BRCA1 mutations. A single variant, BRCA2-8765delAG, was the most recurrent mutation in the series and was found in 12 of 102 families (11.8%) and in 18 of 657 patients (2.7%). The average age at diagnosis was significantly younger in families with BRCA1/2 mutations (48.6 yrs) compared with the age of patients who had no detectable mutation (52.9 yrs; P = 0.039). Moreover, BRCA1/2 mutations were found at a significantly higher rate in families who had at least 1 member with ovarian carcinoma or male breast carcinoma (5 of 12 families; 41.7%) than in families without such an association (10 of 90 families; 11.1%; P = 0.003). CONCLUSIONS:BRCA2 mutations were approximately 6 times more prevalent than BRCA1 mutations. A diagnosis of breast carcinoma before age 50 years, ovarian carcinoma, male breast carcinoma, and 3 affected generations all were associated significantly with BRCA1/2 mutations. Although the current findings provided further support for the hypothesis that additional breast carcinoma susceptibility genes remain to be identified, such indicators of the presence of BRCA1/2 mutations may be useful in counseling patients about undergoing genetic testing. Copyright 2005 American Cancer Society.
Authors: Grazia Palomba; Maria Colombino; Antonio Contu; Bruno Massidda; Giovanni Baldino; Antonio Pazzola; MariaTeresa Ionta; Francesca Capelli; Vittorio Trova; Tito Sedda; Giovanni Sanna; Francesco Tanda; Mario Budroni; Giuseppe Palmieri; Antonio Cossu; Marta Contu; Angelo Cuccu; Antonio Farris; Antonio Macciò; Giuseppe Mameli; Nina Olmeo; Salvatore Ortu; Elisabetta Petretto; Valeria Pusceddu; Luciano Virdis Journal: J Transl Med Date: 2012-08-29 Impact factor: 5.531
Authors: Grazia Palomba; Angela Loi; Eleonora Porcu; Antonio Cossu; Ilenia Zara; Mario Budroni; Mariano Dei; Sandra Lai; Antonella Mulas; Nina Olmeo; Maria Teresa Ionta; Francesco Atzori; Gianmauro Cuccuru; Maristella Pitzalis; Magdalena Zoledziewska; Nazario Olla; Mario Lovicu; Marina Pisano; Gonçalo R Abecasis; Manuela Uda; Francesco Tanda; Kyriaki Michailidou; Douglas F Easton; Stephen J Chanock; Robert N Hoover; David J Hunter; David Schlessinger; Serena Sanna; Laura Crisponi; Giuseppe Palmieri Journal: BMC Cancer Date: 2015-05-10 Impact factor: 4.430
Authors: Milena Casula; Antonio Muggiano; Antonio Cossu; Mario Budroni; Corrado Caracò; Paolo A Ascierto; Elena Pagani; Ignazio Stanganelli; Sergio Canzanella; Mariacristina Sini; Grazia Palomba; Giuseppe Palmieri Journal: BMC Cancer Date: 2009-10-03 Impact factor: 4.430
Authors: Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne Journal: BMC Cancer Date: 2009-07-20 Impact factor: 4.430
Authors: Grazia Palomba; Antonio Cossu; Eitan Friedman; Mario Budroni; Antonio Farris; Antonio Contu; Marina Pisano; Paola Baldinu; Maria C Sini; Francesco Tanda; Giuseppe Palmieri Journal: BMC Cancer Date: 2007-07-19 Impact factor: 4.430
Authors: Grazia Palomba; Mario Budroni; Nina Olmeo; Francesco Atzori; Maria Teresa Ionta; Marina Pisano; Francesco Tanda; Antonio Cossu; Giuseppe Palmieri Journal: Oncol Lett Date: 2014-01-28 Impact factor: 2.967